Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

v3.3.0.814
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
Sep. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 12,413,000 $ 3,970,000
Accounts receivable $ 12,000 122,000
Marketable securities 1,975,000
Prepaid and other current assets $ 632,000 144,000
Mortgage note receivable, current portion 168,000 165,000
Total current assets 13,225,000 6,376,000
Property and equipment, net 369,000 284,000
Deposits 31,000 31,000
Mortgage note receivable, long-term portion 2,374,000 2,431,000
In process research and development 184,966,000 184,966,000
Goodwill 65,195,000 65,195,000
Total assets 266,160,000 259,283,000
Current liabilities:    
Accounts payable 724,000 299,000
Accrued expenses 331,000 394,000
Derivative liabilities 3,096,000 8,464,000
Total current liabilities 4,151,000 9,157,000
Long-term liabilities    
Deferred rent 61,000 62,000
Deferred tax liability 65,195,000 65,195,000
Total long-term liabilities 65,256,000 65,257,000
Total liabilities $ 69,407,000 74,414,000
Series A convertible preferred stock, $0.001 par value; 1,000 shares authorized, 0 and 1,000 issued and outstanding at September 30, 2015 and December 31, 2014, issued in the merger with RFS Pharma, LLC 178,218,000
Stockholders' equity:    
Series B convertible preferred stock, $.001 par value; 5,000 shares authorized; 0 and 1,000 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively 1,000
Common stock, $.001 par value; 800,000 and 200,000 shares authorized, 694,375 and 122,494 issued and outstanding as of September 30, 2015 and December 31, 2014, respectively $ 694,000 123,000
Additional paid-in capital $ 228,166,000 18,725,000
Accumulated other comprehensive income, net of tax 236,000
Accumulated deficit $ (32,107,000) (12,434,000)
Total stockholders' equity 196,753,000 6,651,000
Total liabilities and stockholders' equity $ 266,160,000 $ 259,283,000